FDA Brief

Warning letters Drugs

FDA warning letter to

Age Management Institute Santa Barbara

High riskIssued Apr 18, 2022Posted May 3, 2022Division of Pharmaceutical Quality Operations IV

FDA cited Age Management Institute Santa Barbara for insanitary sterile compounding of IV drugs, including dirty equipment and expired ingredients.

What happened

FDA inspected the facility from March 22 to April 12, 2021, and issued its inspection findings form (Form FDA 483). The investigator found sterile drug products were prepared, packed, or held under insanitary conditions, including no certified ISO 5 clean area, visibly dirty equipment and surfaces, a dirty air vent, carpet in the IV storage and mixing room, and a refrigerator with dripping and standing water touching sterile containers. FDA also said the firm distributed drug products made with expired components, and the firm stopped IV therapy production as of the inspection.

What FDA found

  1. Sterile drug products were prepared under conditions that could contaminate them, which the law calls adulterated.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The facility did not have a certified ISO 5 classified area for sterile compounding.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. Aseptic processing areas had equipment and surfaces that were visibly dirty and difficult to clean, including a hood with a dirty filter and stained, peeling paint.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. An air vent in the IV storage and mixing room was visibly dirty, and part of the floor was covered with carpet.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. A refrigerator with dripping and standing water on an inside shelf was used to store sterile drug products, and containers/closures touched the condensate water.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  6. The firm distributed drug products prepared using expired components.

    FDCA section 301(k) [21 U.S.C. § 331(k)]

What FDA wants

FDA asks the firm to reply in writing within 15 working days with steps taken to address the violations, or to state that it will not resume sterile drug production. If it plans to resume, FDA recommends a comprehensive assessment with a qualified third-party consultant and asks for 15 working days' notice before resuming.

Who should pay attention

  • patients receiving compounded IV therapy
  • clinics and physicians that buy or use compounded sterile drugs
  • compounding pharmacies and sterile compounders

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk